Study of Camizestrant in Patients with ER+/HER2- Early Breast Cancer

This is a Phase III study to help us improve outcomes of patients with ER+/HER2- early breast cancer with intermediate or high risk for disease recurrence. This study is for patients who have completed definitive locoregional therapy and standard adjuvant endocrine therapy for at least 2 years and up to 5 years without disease recurrence. In this study, we want to learn if a new oral "SERD" therapy called Camizestrant is helpful in reducing chance of recurrence. Talk to your Medical Oncologist for more information about this trial.